Please provide your email address to receive an email when new articles are posted on . Treatment with adaptive servo-ventilation for 12 months improved disease-specific quality of life scores. At 12 ...

ORLANDO, Fla. — In a substudy of CAT-HF, patients with HF, sleep-disordered breathing and an implantable cardiac device assigned adaptive servo-ventilation plus optimal medical therapy had a reduction ...

SAN DIEGO, May 13, 2015 /CNW/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was ...

Using Philips PAP solutions, results resurface conversation around ASV therapy use for complex sleep apnea and its potential to improve quality of life Amsterdam, the Netherlands – Royal Philips (NYSE ...

Adaptive servo-ventilation (ASV) therapy increases mortality and should not be used to treat central sleep apnea in heart failure patients with reduced ejection fraction, the SERVE-HF trial shows.

ResMed announced primary results from a multicenter, randomized controlled phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF ...

Miami Beach, Fla. (June 11, 2012)—Many chronic heart failure patients struggle with not just strenuous activity but even the essentials such as moderate exercise and normal breathing. Research ...

Safety Signal of Increased Cardiovascular Mortality Found For ASV Therapy In People With Predominant Central Sleep Apnea and Symptomatic Chronic Heart Failure SAN DIEGO, May 13 /PRNewswire/ -- ResMed ...

On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...

SAN DIEGO, May 13, 2015 /PRNewswire/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint.